LXEO Stock Analysis: Buy, Sell, or Hold?
LXEO - Lexeo Therapeutics, Inc. Common Stock
$4.69
0.24 (5.39%)
▲
5d:
-0.21%
30d:
+3.99%
90d:
-17.28%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When LXEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: LXEO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: LXEO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: LXEO is currently trading at $4.69, which is considered fair relative to its 30-day fair value range of $4.40 to $5.00.
Technical Outlook: Technically, LXEO is in a strong downtrend. Immediate support is located at $4.33, while resistance sits at $5.34. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: LXEO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.60 (+339.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LXEO is in a strong downtrend. Immediate support is located at $4.33, while resistance sits at $5.34. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: LXEO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.60 (+339.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.40 -
$5.00
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
93.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- BULLISH: Trading 339.2% below Wall St target ($20.60)
Trading Range Analysis
30-Day Trading Range
$4.40 -
$5.00
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.63
(13.5%)
Support & Resistance Levels
Support Level
$4.33
Resistance Level
$5.34
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.51
Wall Street Target
$20.60
(+339.2%)
Share & Embed Analysis
Last updated: July 02, 2026 10:43 PM ET
Data refreshes hourly during market hours. Next update: 11:43 PM
Data refreshes hourly during market hours. Next update: 11:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LXEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Richard Nolan Townsend
SELL
55000 shares
2026-04-06
Jose Manuel Otero
SELL
3016 shares
2026-02-18
Richard Nolan Townsend
SELL
10173 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 64 BUY |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$123 | 57 HOLD |
